Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Oakes

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 2, 2006
Rasagiline improves quality of life in patients with early Parkinson's diseaseKevin M Biglan, Steven Schwid, Shirley Eberly, et al.
Obstetrics and Gynecology|August 25, 2010
Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trialDavid C Foster, Merrill Beth Kotok, Li-Shan Huang, et al.
Inhalation Toxicology|January 21, 2015
Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1Mark W Frampton, Anthony Pietropaoli, Michael Dentler, et al.
Annals of Clinical and Translational Neurology|June 8, 2017
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)Kevin M Biglan, David Oakes, Anthony E Lang, et al.
CNS Drugs|January 17, 2025
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington DiseaseSamuel Frank, Claudia M Testa, Jody Goldstein, et al.
BMC Health Services Research|December 17, 2022
Using a stakeholder-engaged, iterative, and systematic approach to adapting collaborative decision skills training for implementation in VA psychosocial rehabilitation and recovery centersEmily B H Treichler, Robert Mercado, David Oakes, et al.
Neurology|August 23, 2013
HTRF analysis of soluble huntingtin in PHAROS PBMCsMiriam Moscovitch-Lopatin, Rachel E Goodman, Shirley Eberly, et al.
Environmental Health Perspectives|May 1, 2012
Are ambient ultrafine, accumulation mode, and fine particles associated with adverse cardiac responses in patients undergoing cardiac rehabilitation?David Q Rich, Wojciech Zareba, William Beckett, et al.
Clinical Neuropharmacology|June 4, 2008
A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank, William Ondo, Stanley Fahn, et al.
CNS Drugs|October 15, 2022
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudySamuel Frank, Claudia Testa, Mary C Edmondson, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Movement Disorders : Official Journal of the Movement Disorder Society|February 2, 2006
Rasagiline improves quality of life in patients with early Parkinson's diseaseKevin M Biglan, Steven Schwid, Shirley Eberly, et al.
Obstetrics and Gynecology|August 25, 2010
Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trialDavid C Foster, Merrill Beth Kotok, Li-Shan Huang, et al.
Inhalation Toxicology|January 21, 2015
Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1Mark W Frampton, Anthony Pietropaoli, Michael Dentler, et al.
Annals of Clinical and Translational Neurology|June 8, 2017
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)Kevin M Biglan, David Oakes, Anthony E Lang, et al.
CNS Drugs|January 17, 2025
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington DiseaseSamuel Frank, Claudia M Testa, Jody Goldstein, et al.
BMC Health Services Research|December 17, 2022
Using a stakeholder-engaged, iterative, and systematic approach to adapting collaborative decision skills training for implementation in VA psychosocial rehabilitation and recovery centersEmily B H Treichler, Robert Mercado, David Oakes, et al.
Neurology|August 23, 2013
HTRF analysis of soluble huntingtin in PHAROS PBMCsMiriam Moscovitch-Lopatin, Rachel E Goodman, Shirley Eberly, et al.
Environmental Health Perspectives|May 1, 2012
Are ambient ultrafine, accumulation mode, and fine particles associated with adverse cardiac responses in patients undergoing cardiac rehabilitation?David Q Rich, Wojciech Zareba, William Beckett, et al.
Clinical Neuropharmacology|June 4, 2008
A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank, William Ondo, Stanley Fahn, et al.
CNS Drugs|October 15, 2022
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudySamuel Frank, Claudia Testa, Mary C Edmondson, et al.
Pageof 12